300 related articles for article (PubMed ID: 31428721)
1. Impact of
Bange E; Marmarelis ME; Hwang WT; Yang YX; Thompson JC; Rosenbaum J; Bauml JM; Ciunci C; Alley EW; Cohen RB; Langer CJ; Carpenter E; Aggarwal C
JCO Precis Oncol; 2019; 3():. PubMed ID: 31428721
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and immune phenotypes associated with
Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
5. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Pavan A; Bragadin AB; Calvetti L; Ferro A; Zulato E; Attili I; Nardo G; Dal Maso A; Frega S; Menin AG; Fassan M; Calabrese F; Pasello G; Guarneri V; Aprile G; Conte P; Rosell R; Indraccolo S; Bonanno L
Transl Lung Cancer Res; 2021 Jan; 10(1):202-220. PubMed ID: 33569305
[TBL] [Abstract][Full Text] [Related]
6. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
7. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
8. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
9. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
10. STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.
Krishnamurthy N; Goodman AM; Barkauskas DA; Kurzrock R
Eur J Cancer; 2021 May; 148():215-229. PubMed ID: 33744718
[TBL] [Abstract][Full Text] [Related]
11. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
Torralvo J; Friedlaender A; Achard V; Addeo A
Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
13. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
Schabath MB; Welsh EA; Fulp WJ; Chen L; Teer JK; Thompson ZJ; Engel BE; Xie M; Berglund AE; Creelan BC; Antonia SJ; Gray JE; Eschrich SA; Chen DT; Cress WD; Haura EB; Beg AA
Oncogene; 2016 Jun; 35(24):3209-16. PubMed ID: 26477306
[TBL] [Abstract][Full Text] [Related]
14. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.
Sun Y; Li Z; Jian H; Xia L; Lu S
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887766
[TBL] [Abstract][Full Text] [Related]
15. Primary Resistance to Immune Checkpoint Blockade in an
Kwack WG; Shin SY; Lee SH
Onco Targets Ther; 2020; 13():8901-8905. PubMed ID: 32982282
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic Characteristics and Outcomes for Patients With
Cooper AJ; Muzikansky A; Lennerz J; Narinesingh F; Mino-Kenudson M; Hung YP; Piotrowska Z; Dagogo-Jack I; Sequist LV; Gainor JF; Lin JJ; Heist RS
JTO Clin Res Rep; 2022 Sep; 3(9):100390. PubMed ID: 36118132
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
Rosellini P; Amintas S; Caumont C; Veillon R; Galland-Girodet S; Cuguillière A; Nguyen L; Domblides C; Gouverneur A; Merlio JP; Bezin J; Girodet PO
Eur J Cancer; 2022 Sep; 172():85-95. PubMed ID: 35759814
[TBL] [Abstract][Full Text] [Related]
19. The role of distinct co-mutation patterns with
Wang S; Jiang M; Yang Z; Huang X; Li N
Genes Dis; 2022 Jan; 9(1):245-251. PubMed ID: 35005121
[No Abstract] [Full Text] [Related]
20. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
